跳至主要内容
临床试验/NCT03723304
NCT03723304已完成不适用

The Intention-to-treat Effect of Bridging Therapies in the Setting of Milan-in Patients Waiting for Liver Transplantation

European Hepatocellular Cancer Liver Transplant Group1 个研究点 分布在 1 个国家目标入组 1,083 人开始时间: 2018年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,083
试验地点
1
主要终点
Tumour-specific liver transplant failure rate

研究概览

简要总结

In patients with hepatocellular cancer (HCC) meeting the Milan Criteria (MC), the usefulness of loco-regional therapies (LRT) in the context of liver transplantation (LT) is still debated. The inconsistent literature data are the result of initial selection biases among treated and untreated patients. In order to overcome these shortcomings, an inverse probability of treatment weighting (IPTW) analysis was done in a large patient cohort. After using a competing-risk analysis, the primary end-point of the study aims at identifying the risk factors of HCC-specific LT failure, defined as pre-LT tumour-related drop-out or post-LT recurrence.

详细描述

Liver transplantation (LT) is the best curative treatment of hepatocellular cancer (HCC) developed in an underlying liver disease. LT is considered as an oncologic successful procedure when a long-term post-transplant tumour-free survival is obtained. Conversely, a failure is equal to pre-transplant drop-out, post-transplant tumour recurrence or death. Due to the allograft scarcity, a HCC patient waiting for a LT is most often treated using neo-adjuvant loco-regional therapies (LRT) in order to minimise the risk of drop-out. When the tumour burden meets the Milan Criteria (MC) at moment of diagnosis, such an approach is called "bridging towards LT".

Two recent international guidelines underlined the importance of the bridging strategy, due to its potential to reduce the risk of pre-LT drop-out and post-LT recurrence. This is especially valid in the case in which a partial/complete tumour response is achieved before LT. Unfortunately, the quality of the evidence obtained from the currently available literature is low due to the lack of randomized controlled trials (RCT). Actually, it is inconceivable to realize RCT in this setting because of logistical and, even more, ethical reasons. Consequently, the majority of reported studies just compare post-LT outcome of treated and untreated patients, failing thereby to analyse the clinical course from an intention-to-treat (ITT) point of view.

Even when looking at studies including the waiting list period, one should keep in mind that substantial differences may exist among initially bridged vs untreated HCC patients regarding tumour burden. In order to overcome these limits, a retrospective analysis of a large European population of MC-IN HCC patients listed for LT was done. After "balancing" this cohort with an inverse probability of treatment weighting (IPTW), we investigated the risk factors for tumour-specific LT failure, especially focusing at the role of LRT.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • adults (≥18-year old) listed for liver transplant with a morphologic and/or histologic confirmed hepatocellular cancer

排除标准

  • Milan Criteria-out status at first referral
  • transplantation or de-listing before January 1, 2001
  • other means of loco-regional treatments such as partial hepatectomy, trans-arterial radio-embolization or external radiotherapy
  • misdiagnosed mixed hepatocellular-cholangiocellular cancer or cholangiocellular cancer

结局指标

主要结局

Tumour-specific liver transplant failure rate

时间窗: up to 5 years from first referral

Any case of tumor-related drop-out during the waiting list period or post-transplant recurrence

次要结局

未报告次要终点

研究者

发起方
European Hepatocellular Cancer Liver Transplant Group
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验